Non-Hodgkins Lymphoma Treatment Market to See Incredible Growth By 2026


Non-Hodgkins Lymphoma (NHL) is a type of cancer that occurs due to abnormal functioning of B or T lymphocytes and leukocytes. Around 80% of the lymphomas arise in developing B cells and the remainder arise in developing T cells. This generally occurs in bone marrow, lymph nodes, spleen, blood and other organs that are part of lymphatic system. The patients suffering from non-Hodgkin’s lymphoma are observed with symptoms like fever, weight loss, swelling of lymph nodes, anorexia, fatigue and dyspnoea. Treatment of the NHL depends whether the cells are fast or slow growing and also whether it is spread in one area or different areas of the body. Treatment options for NHL include immunotherapy, chemotherapy, stem cell transplantation, targeted therapy, monoclonal antibody therapy and radiation therapy. If blood thickens in the patient due to presence of antibodies then plasmapheresis can also be carried out. Various products available for treating lymphoma include Deltasone, Adcertis, Folotyn, Adriamycin, Prednicot, Leukeran, Velcade, Thioplex and Decadron.
The launch of new drugs in the near future expected to support the growth of non-hodgkins lymphoma treatment market. For instance, a new drug Axicabtagene ciloleucel, received priority review status to get commercialize for the treatment of non-hodgkins lymphoma as a second line therapy. This drug is expected to launch in later of year 2017.

Request For Sample Copy This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/547

Non-Hodgkins lymphoma treatment market taxonomy:
On the basis of type of non-hodgkins lymphoma, the non-hodgkins lymphoma treatment market is classified into:
  • B-cell lymphoma
  • T-cell lymphoma
Rituxan drug which is used to treat NHL and had been a front-line treatment regimen, though there has been an increasing rituximab resistance. To overcome this resistance, there has been various R&D practices that will create space in the market. For instance, Roche, Inc. is conducting phase IIIstudy of Gazyva/Gazyvaro in people with previously untreated with diffuse large B-cell lymphoma. . The extension of already marketed drugs such as Velcade as a front-line therapy for mantle cell lymphoma (MCL), Revlimid for maintenance therapy of diffuse large B-cell lymphoma (DLBCL) and Adcetris for CD30 T-cell lymphoma would be further contributing towards the non-hodgkins lymphoma treatment market growth. In 2016, the U.S. Government allocated US$ 5.2 billion to the National Cancer Institute (NCI) for cancer research and training purpose.

Increase in incidence of NHL will fuel the market
By geography, North America holds the major share in the market because of the high incidence rate of blood cancers in the U.S. According to Leukemia and Lymphoma Society, non-Hodgkin lymphoma is the seventh most common cancer in the U.S. and fifth in the UK. The National Cancer Institute estimated 72,580 new cases and 20,150 deaths in 2016 due to NHL in the U.S. According to the American Cancer Society, 20 cases of NHL, 6 cases of myeloma and 13 cases of leukemia were estimated per 100,000 population in 2014 in the U.S. Moreover, the organization states that, around 6 out of 10 people diagnosed with non-Hodgkin lymphoma are aged 65 and above. Also, NHL is much more common in men than in women.

Strategies implemented by competitors to drive the market:
Key players in the non-Hodgkin’s lymphoma treatment market inlcude Novartis International AG, Pharmacyclics, Inc., Bayer AG, F. Hoffmann LA Roche, Amgen, Inc., Eli Lilly and Company, Nordic Nanovector A/S and AbbVie, Inc. The prominent players are undertaking collaborative strategies for clinical research to yield new drugs which will aid them to gain competitive advantage. For instance, Novartis AG collaborated with Aduro Biotech in 2015 for clinical trial of novel immuno-oncology product such as ADU-S100 that is expected to treat non-Hodgkin’s lymphoma. Also, taking a step ahead, Roche launched a global network of immunotherapy centers named as Immunotherapy Centers of Research Excellence (imCORE) Network in 2016. This network intends to develop potential therapies for non-Hodgkin’s lymphoma by developing drugs that will simulate one’s immune system to fight the disease.


About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Comments

Post a Comment

Popular posts from this blog

Medical Automation Market Analysis, Growth, Size, Share, Trends, Supply Demand and Forecast to 2026

Medical automation is a technology used to minimize medical errors, promote better management of chronic illness, and to enable healthcare professionals to anticipate prognosis. It controls the diagnostic, monitoring, and therapeutic machineries that serves the major responsive tasks into the hospitals. It also increases the predictability of outcome when patients follow a standardized care path supported by automation. Moreover, automation can help to detect when a patient has deviated from recommended care plan so the care team can intervene. The technology implementation enhances efficiency of hospitals by reducing the process time and improving accuracy of a medical procedures. Medical automation in hospitals such as using robotic assisted systems for health check-ups, is also propelling the growth of the market and in turn improving patient safety. Hospitals are adopting the medical robotics to reduce the HAIs rates in healthcare facility and to provide cleaner and saf...
Read more

Medical Disposables Market to Witness a Pronounce Growth by 2026

Medical disposables are products that are used in hospitals or in various medical fields for prevention of infections and for safety measures to meet the medical standards. The medical disposables are important to lower the risk of cross-contamination and infections that is a primary aim of healthcare professionals and governments globally. Medical disposables includes conventional syringes, disposable medical catheters, isolation gowns, procedure kits and trays, blood glucose tes t strips, and wound care products. The medical disposables are the essential component of every hospital and they have one time usage and need to be disposed after use. Medical disposables are used in surgery, drug and fluid delivery, wound management, diagnostic testing, patient examination, incontinence management, sterilization, and to reduce the discomfort of patient. The need of safety and prevention from infections for the various medical fields such as surgical wear, hygiene, anesthesia and ped...
Read more

Cancer Vaccines Market Taking New Steps to Meet the Challenges With Major Key Companies

Cancer is the second leading cause of morbidity and mortality worldwide. Major cause of cancer is gene mutation and rarely due to inherited genes. On the basis of the type of cell it initiates to form cancerous with, it is divided into carcinoma, lymphomas, leukaemias, brain tumors, and sarcomas. According to World Health Organization (WHO), 2017, nearly 1 in 6 deaths is due to cancer globally and around 70% of deaths from cancer occur in low- and middle-income countries. Moreover, it is projected that for next two decades, 70% of new cases are expected to be diagnosed globally. Advent of cancer vaccines can significantly reduce this numbers and lead a cancer-free life for the global population. Key players in the global cancer vaccines market include, Astrazeneca Plc. (Medimmune, LLC.), Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Aduro BioTech Inc., Sanpower Group, Astellas Pharma Inc., CSL Limited, Pfizer Inc., and Serum Institute of India Pvt. Ltd. Dow...
Read more